Özgür Aydın TOSUN, Pınar BATU, l Arzu ARINKAN³, Ertuğrul YILMAZ, Çetin ÇAM, Ateş KARATEKE

Gestasyonel Trofoblastik Hastalıklar ve Takip Oranları

Amaç: Gestasyonel trofoblastik hastalık (GTH), anormal fertilizasyonun bir sonucu olarak gelişen, gebelikte trofoblastın anormal proliferasyonu sonucu endometrium ve myometriumu invazyonu ile karakterize bir hastalık grubudur. Kesin tanı, vakum küretaj sonrası alınan örneğin histopatolojik olarak değerlendirilmesi ile konur. Bu çalışmayla hastanemizde histopatolojik olarak GTH tanısı almış olguların oranlarını ve klinik takip düzeylerinin belirlenmesini amaçladık.Gereç ve yöntemler: 2000-2008 yılları arasında hastanemizde doğum ve abortus yapan olgular ile histopatolojik olarak GTH tanısını alan olguların medikal kayıtları retrospektif olarak incelenmiştir. Çalışmamızda verilerin değerlendirilmesinde SPSS 12.0 paket programı kullanıldı.Tek değişkenli analizde Pearson Ki -kare analizi kullanıldı. P

Gestational trophoblastic disease and Follow-up Ratio

Gestational trophoblastic disease is a heterogeneous group of diseases characterized by invasion of abnormally proliferating trophoblastic tissue to the endometrium and myometrium. Diagnosis is histopathologically following vacuum curettage. Purpose of this research is to determine the follow-up ratio of patients who had GTD. Material and methods: This retrospective study was performed including the patients who had GTH diagnosis at Zeynep Kamil Hospital between 2000 and 2008. Statistical analysis was performed using the SPSS 12 program. Chi-square test was used for statistical analysis. P values were considered to be statistically significant at P < 0.05. Results: 103951 patients were included in this research. 257 of them had GTH diagnosis histopathologically. 5 of them (%1.94) had choriocarcinoma , 3 of them (%1.16) had placental site trophoblastic tumors and 249 of them (%96) had hydatidiform mole .62 of hydatidiform mole cases (%25) did not visit doctors regularly. This ratio is %21 at partial mole cases and %25 complete mole cases respectively. Conclusion: Patients who had GTH diagnosis should be followed regularly. Regular follow up at specialized clinics is extremely important for the proper management of the disease.

PDF

___

1) Lurain JR: Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol 2010;204(1):11-8
2) McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ; The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer. 2010;102(5):810-4
3) Sebire NJ, Seckl MJ. Gestational trophoblastic disease: current management of hydatidiform mole. BMJ 2008;337:1193
4) Seckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, Newlands ES Choriocarcinoma and partial hydatidiform moles. Lancet, 2000;356: 36–39
5) Dighe M, Cuevas C, Moshiri M, Dubinsky T, Dogra VS. Sonography in fi rst trimester bleeding. J Clin Ultrasound 2008;36(6):352–366.
6) Berkowitz RS, Goldstein DP, Bernstein MR. Natural history of partial molar pregnancy. Obstet Gynecol 1985;66: 677-681
7) Cetin M, Balta O, Duran B, Guvenal T, Yanar T. A Retrospective Study of Molar Pregnancy Cases Submitted to our Clinic. C. Ü. Tıp Fakültesi Dergisi 2004; 26 (1): 18 – 22
8) Parazzini F, La Vecchia C, Pampallona S, Franceschi S. Reproductive patterns and risk of gestational trophoblastic disease. Am J Obstet Gynecol 1985; 152: 866-70.
9) Steigrad SJ. Epidemiology of gestational trophoblastic diseases. Best Practice & Research Clinical Obstetrics & Gynaecology 2003;17(6), 837-847
10) Acosta-Sison H. Observation which may indicate the aetiology of hydatidiform mole and explain its high incidence in the Philippines and Asiatic countries. Philippine Journal of Surgery 1959; 14: 290–293.
11) Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG 2002;109(1):99–102.
12) Weigle DS, Bukowski TR, Foster DC, et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest 1995; 96:2065- 2070
13) Terek MC, Akman L, Zekioglu O, Dikmen Y, Erhan Y, Ulukus M; İnvaziv Mol Hidatiform: Olgu Sunumu ve Literatür Derlemesi: Ege Tıp Dergisi 44(2) : 127 - 130, 2005
14) Scott JR, Disaia PJ, Hammond CB : Danforth’s Obstetrics and Gynecology. Philadelphia, Lippincot&Wilkins, 9th edition 2003;1039-1053
15) Harris RD, Cho C, Wells WA. Sonography of the placenta with emphasis on pathological correlation. Semin Ultrasound CT MR 1996;17(1):66–89.
16) Zalel Y, Gamzu R, Weiss Y, et al. Role of color Doppler imaging in diagnosing and managing pregnancies complicated by placental chorioangioma. J Clin Ultrasound 2002;30(5):264–269.
17) Soper JT, Evans AC, Conoway MR: Evaluation of prognostic factors and staging in gestational trophoblastic tumors. Obstet Gynecol 1994; 84: 969-972
18) Hancock BW, Newlands ES, Berkowitz RS: Gestational trophoblastic disease. 1st ed Chaman&Hall Medical, New York, 1997.
19) Sand PK, Lurain JR, Brewer JI. Repeat gestational trophoblastic disease. Obstet Gynecol, 1984; 63: 140-4.
20) Lorigan PC, Sharma S,Bright N, Coleman RE, Hancock BW. Characteristics of Women with recurrent molar pregnancies. Gynecol Oncol 2000;78: 288-92.